Publications by authors named "Chloe Pek Sang Tang"
Article Synopsis
- The study examines the effectiveness of covalent Bruton's tyrosine kinase inhibitors (BTKis) in chronic lymphocytic leukemia (CLL), focusing on how resistance develops, particularly with mutations in the BTK gene.
- A significant mutation, BTK Leu528Trp, was found more frequently in patients treated with the newer drug zanubrutinib compared to older drug ibrutinib, indicating a potential resistance mechanism.
- Patients with the BTK Leu528Trp mutation showed cross-resistance when treated with the noncovalent BTKi pirtobrutinib, but they improved with venetoclax-based treatment, suggesting important implications for future treatment sequencing in CLL.
The development of bruton tyrosine kinase inhibitors (BTKi) has been a significant advancement in the treatment of chronic lymphocytic leukemia and related B-cell malignancies. As experience in using ibrutinib increased, the first drug to be licensed in its class, atrial fibrillation (AF) emerged as an important side effect. The intersection between BTKi therapy for B-cell malignancies and AF represents a complex area of management with scant evidence for guidance.
View Article and Find Full Text PDF